Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
05/2005
05/31/2005US6900049 Adenovirus vectors containing cell status-specific response elements and methods of use thereof
05/31/2005US6900043 Phosphatases which activate map kinase pathways
05/31/2005US6900038 eNOS mutations useful for gene therapy and therapeutic screening
05/31/2005US6900035 Comprises human papilloma virus (HPV) fusion between mycobacterial chaperone protein and viral E6 protein for use in treating tumors
05/31/2005US6900032 Human PTTG polypeptide and method for producing it
05/31/2005US6900010 Taking a culture of recombinant cells comprises a reporter sequence; contacting cell culture with a sample containing HIV; adding a tester agent to the cell culture; and detecting change in a level of expression of reporter gene in culture
05/31/2005US6899881 H. PYLORI FlbA POLYPEPTIDES, IMMUNOGENIC AND VACCINATING COMPOSITIONS COMPRISING H. PYLORI FlbA POLYPEPTIDES, AND COMPOSITIONS FOR DETECTION OF AN INFECTION COMPRISING H. PYLORI FlbA POLYPEPTIDES
05/31/2005US6899871 Gene delivery system and methods of use
05/26/2005WO2005047519A2 Lsamp and nore 1 down-regulation in clear cell renal cell carcinomas
05/26/2005WO2005047497A1 High-titer retroviral packaging cells
05/26/2005WO2005047477A2 Interspersed repetitive element rnas as substrates, inhibitors and delivery vehicles for rnai
05/26/2005WO2005047473A2 Single vector dual gene therapy for pulmonary hypertension
05/26/2005WO2005047465A2 Method and antisense compound for potentiating anti-cancer agents
05/26/2005WO2005047458A2 Modified recombinant vaccina viruses and other microorganisms, uses thereof
05/26/2005WO2005047315A2 Optimized expression of hpv 58 l1 in yeast
05/26/2005WO2005046732A2 Methods and compositions for the inhibition of hiv-1 replication
05/26/2005WO2005046731A1 Interference with c-maf function in multiple myeloma
05/26/2005WO2005046622A2 Custom vectors for treating and preventing pancreatic cancer
05/26/2005WO2005046621A2 Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
05/26/2005WO2005046614A2 System for treating and preventing breast cancer
05/26/2005WO2005046612A2 Hydroxy piperidine derivatives to treat gaucher disease
05/26/2005WO2005046611A2 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
05/26/2005WO2005046605A2 Compositions and methods of treating neurological diseases
05/26/2005WO2005046594A2 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
05/26/2005WO2005046585A2 Vps35-based assays and methods for treating alzheimer’s disease
05/26/2005WO2005046572A2 Targeted delivery of controlled release polymer systems
05/26/2005WO2005046570A2 Human stem cell materials and methods
05/26/2005WO2005046564A2 Diagnosis and treatment of liver fibrosis
05/26/2005WO2005046450A2 Method for diagnosis and treatment of pulmonary disorders
05/26/2005WO2005046434A2 Compositions and methods for diagnosing and treating mental disorders
05/26/2005WO2005025624A3 The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases
05/26/2005WO2005018537A3 Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors
05/26/2005WO2005009363A3 Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies
05/26/2005WO2005009217A3 Diagnosis of pre-cancerous conditions using pcdgf agents
05/26/2005WO2005003158A3 Compositions and methods for increasing bone mineralization
05/26/2005WO2005000318B1 Method of inducing apoptosis and inhibiting cardiolipin synthesis
05/26/2005WO2004110603A3 Method for preparation of particles from solution-in-supercritical fluid or compressed gas emulsions
05/26/2005WO2004097039A3 Biosynthetic platform for cardioprotective gene expression using neonatal immature and fetal heart tissue
05/26/2005WO2004073604A3 Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity
05/26/2005WO2004070008A3 Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
05/26/2005WO2003053341A3 Antisense modulation of ship-1 expression
05/26/2005US20050113329 Contacing cell/body fluid with antibody which binds human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide; for inhibiting tumor growth; gene expression inhibition; immunization
05/26/2005US20050113328 Method and antisense compound for potentiating anti-cancer agents
05/26/2005US20050113326 Gene expression inhibition; connective tissue growth factor modulators; nucleosides, phosphorothioate/phosphodiester linkages; metabolic diseases, diabetes
05/26/2005US20050113325 Linked/conjugated to lipid, fatty acid, and/or sterol; for inhibiting cancer cell proliferation
05/26/2005US20050113324 For treatment/prevention of cancer; retrotransposons; enzyme inhibitors/antagonists (antisense agents, nucleoside analog 3'-azido-2',3'-dideoxythymidine) block lengthening of telomeres in telomerase negative cells; gene expression inhibition; host cells; kits
05/26/2005US20050113323 Introducing antisense nucleotides which are complementary to untranslated region of prostate tumor inducing gene
05/26/2005US20050113322 Oligonucleotides which hybridize to inhibit expression; nucleosides; chimera; colloids; cardiovascular disorders; nervous system disorders; diabetes; ischemia/reperfusion injuries
05/26/2005US20050113291 Use of a substance which binds to and initiates signaling of the human SARP-1 receptor or a substance which stimulates release or potentiates the activity of endogenous SARP-1 for the manufacture of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis
05/26/2005US20050113284 Drug for regenerating tissue and vessel and method therefor
05/26/2005US20050112765 Genetic engineering polypeptides containing capsids; cell transduction
05/26/2005US20050112763 Control forming within genome of cells, histone protein; induce methylation
05/26/2005US20050112752 Method for the purification of alphavirus replicon particles
05/26/2005US20050112745 Transferases
05/26/2005US20050112709 Histone h3methyltransferase polypeptide
05/26/2005US20050112668 Determination sensitivity for development fat metabolism diosrders by comparison of gene expression levels
05/26/2005US20050112666 Tumor necrosis factor related ligand
05/26/2005US20050112665 Novel VEGF-like factor
05/26/2005US20050112638 Screening agent that moderates post-transcriptional control of angiotensin receptors; hypotensive agents
05/26/2005US20050112596 APRIL-A novel protein with growth effect
05/26/2005US20050112568 Dgks as modifiers of the p53 pathwha and methods of use
05/26/2005US20050112563 Sub-sequences of 2'-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H enzyme; diagnostics; antisense therapeutics
05/26/2005US20050112187 Nucleic acid that expresses a polypeptide such as a cytokine and a phospholipid, both having cytotoxic activity; synergistic combination; side effect reduction
05/26/2005US20050112185 Positively charged lipid and liposome with the lipid
05/26/2005US20050112145 Dna vaccines coding antigen
05/26/2005US20050112141 Compositions and methods for treatment of neoplastic disease
05/26/2005US20050112110 Isolated polynucleotide sequences; controlling neovasculization; cell growth regulators
05/26/2005US20050112109 Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
05/26/2005US20050112108 Controlling gene expression of tumor suppression gene; binding to transcription factor
05/26/2005US20050112107 Prevent adhesion of teeth; using argine, glycine, aspartic acid tripeptides
05/26/2005US20050112104 Forming cardiomyocytes in vivo using mesenchymal stem cells; cell differentiation
05/26/2005US20050112103 Genetic engineered vectors encoding human low density lipoproteins ; control sequencing, gene expressionin heptacytes; anticholesterol agents; antilipemic agents
05/26/2005US20050112102 Viral proteins which stimulating immunology response
05/26/2005US20050112101 Methods of treating restenosis
05/26/2005US20050112100 Sp1 and Sp3 targeted cancer therapies and therapeutics
05/26/2005US20050112098 Insertion nucleic acid isequences nto cells; retrovirus glycoproteins; respiratory system disorders such as cystic fibrosis
05/26/2005US20050112096 Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
05/26/2005US20050112095 Internal ribosome entry sites for recombinant protein expression
05/26/2005CA2545938A1 High-titer retroviral packaging cells
05/26/2005CA2545435A1 Hydroxy piperidine derivatives to treat gaucher disease
05/26/2005CA2545433A1 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
05/26/2005CA2545260A1 Compositions and methods for modulating c-rel-dependent cytokine production
05/26/2005CA2545183A1 Custom vectors for treating and preventing pancreatic cancer
05/26/2005CA2545182A1 Improved methods and compositions for rna interference
05/26/2005CA2545164A1 Recombinant vectors expressing mucin and carcinoembryoinic antigen
05/26/2005CA2545152A1 Compositions and methods of treating neurological diseases
05/26/2005CA2544923A1 Method and antisense compound for potentiating anti-cancer agents
05/26/2005CA2544591A1 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
05/26/2005CA2543811A1 Compositions and methods for diagnosing and treating mental disorders
05/26/2005CA2541941A1 Anti-bacterial phage tail compositions and uses thereof
05/25/2005EP1533380A2 Recombinant protein production in a human cell comprising at least one E1 protein of adenovirus
05/25/2005EP1532987A1 Agents for gene therapeutic for cerebrovascular disorders
05/25/2005EP1532277A2 Single nucleotide polymorphisms sensitively predicting adverse drug reactions (adr) and drug efficacy
05/25/2005EP1532271A2 Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
05/25/2005EP1532259A1 Non-human herpesviruses as vectors
05/25/2005EP1532255A1 Methods of delivering gene therapy agents
05/25/2005EP1532254A2 Helper virus-free herpesvirus amplicon particles and uses thereof
05/25/2005EP1532253A1 Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine
05/25/2005EP1532251A1 Human acid sensing ion channel 2b (hasic2b), process for producing the same, and its use
05/25/2005EP1532246A2 Genetic suppression and replacement
1 ... 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 ... 870